LEO Pharma – a company focused on medical dermatology has revealed positive results from its DELTA 2 trial.
The research is the second of two phase 3 clinical trials incorporating delgocitinib cream – an investigational topical pan-Janus kinase (JAK)-inhibitor – which treats adults with moderate-to-severe chronic hand eczema (CHE).
During the research, the treatment met its primary and secondary endpoints with a significant improvement in CHE following 16 weeks of treatment, compared to vehicle. Furthermore, the treatment was well-tolerated, while all or most of the symptoms were cleared early on.
Key secondary endpoints also included reduction of pain and pain scores measured by the ‘hand eczema symptom diary’ from baseline to week 16, as well as at least a 75% improvement from baseline and at least 90% improvement from baseline on hand eczema.
Meanwhile, patients who completed 16 weeks of treatment in both DELTA 1 or DELTA 2 trials were offered participation in the DELTA 3 extension trial to evaluate the long-term effects of delgocitinib cream.
Continued analysis of the data set will be conducted to determine the overall potential of delgocitinib cream – again, in the treatment of adults with moderate-to-severe CHE.
Jörg Möller, executive vice president, global research and development at LEO Pharma, was encouraged by the latest results: “It is incredibly exciting to see the level of consistency that our DELTA 2 results show in line with the positive DELTA 1 results announced late last year.”
He added: “CHE is a condition that we know can have a hugely negative impact on patient quality of life, physical functioning, and ability to work. These results bring us one step closer towards establishing delgocitinib as a best-in-class innovative topical treatment for patients affected by this hard-to-treat disease.”
by John Pinching
Source: pharmatimes.com
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
